<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>NK510 &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/nk510/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Tue, 20 Oct 2026 15:21:57 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.3</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>NK510 &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Phase I NK510-PD-1 combination shows preliminary safety in nine lung cancer patients</title>
		<link>https://bioengineer.org/phase-i-nk510-pd-1-combination-shows-preliminary-safety-in-nine-lung-cancer-patients/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Tue, 20 Oct 2026 15:21:57 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Cancer immunotherapy]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[dose escalation]]></category>
		<category><![CDATA[natural killer cells]]></category>
		<category><![CDATA[NK510]]></category>
		<category><![CDATA[non-small cell lung cancer]]></category>
		<category><![CDATA[PD-1 blockade]]></category>
		<category><![CDATA[phase]]></category>
		<category><![CDATA[Phase I trial]]></category>
		<category><![CDATA[TIGIT]]></category>
		<category><![CDATA[treatment safety]]></category>
		<category><![CDATA[tumor microenvironment]]></category>
		<guid isPermaLink="false">https://bioengineer.org/?p=441363</guid>

					<description><![CDATA[A nine-patient phase I trial found that TIGIT-disrupted NK510 could be combined with PD-1 blockade without observed dose-limiting toxicities in advanced non-small cell lung cancer, while preliminary efficacy estimates remained highly uncertain.]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">441363</post-id>	</item>
	</channel>
</rss>
